Stock News

Horizon Pharma Plc (Put) (HZNP) Shareholder Bank Of America Has Trimmed Holding by $43.45 Million as Share Price Declined; Abbvie (ABBV) Stock Declined While Bedell Frazier Investment Counseling Decreased Holding by $7.76 Million

AbbVie Inc. (NYSE:ABBV) Logo

Bedell Frazier Investment Counseling Llc decreased its stake in Abbvie Inc (ABBV) by 97.44% based on its latest 2017Q4 regulatory filing with the SEC. Bedell Frazier Investment Counseling Llc sold 80,783 shares as the company’s stock declined 6.31% with the market. The institutional investor held 2,125 shares of the major pharmaceuticals company at the end of 2017Q4, valued at $205,000, down from 82,908 at the end of the previous reported quarter. Bedell Frazier Investment Counseling Llc who had been investing in Abbvie Inc for a number of months, seems to be less bullish one the $169.15B market cap company. The stock increased 0.58% or $0.61 during the last trading session, reaching $106.6. About 3.06 million shares traded. AbbVie Inc. (NYSE:ABBV) has risen 39.20% since May 21, 2017 and is uptrending. It has outperformed by 27.65% the S&P500.

Bank Of America Corp decreased its stake in Horizon Pharma Plc (Put) (HZNP) by 99.62% based on its latest 2017Q4 regulatory filing with the SEC. Bank Of America Corp sold 3.10 million shares as the company’s stock declined 6.58% with the market. The institutional investor held 11,800 shares of the major pharmaceuticals company at the end of 2017Q4, valued at $172,000, down from 3.12 million at the end of the previous reported quarter. Bank Of America Corp who had been investing in Horizon Pharma Plc (Put) for a number of months, seems to be less bullish one the $2.47 billion market cap company. The stock decreased 0.93% or $0.14 during the last trading session, reaching $14.97. About 1.51M shares traded. Horizon Pharma Public Limited Company (NASDAQ:HZNP) has declined 6.20% since May 21, 2017 and is downtrending. It has underperformed by 17.75% the S&P500.

Since December 14, 2017, it had 0 insider purchases, and 11 sales for $47.70 million activity. 70,928 shares valued at $8.31 million were sold by CHASE WILLIAM J on Wednesday, February 28. GONZALEZ RICHARD A also sold $976,084 worth of AbbVie Inc. (NYSE:ABBV) on Wednesday, February 28. Michael Robert A. sold $512,853 worth of stock or 4,294 shares. SEVERINO MICHAEL sold 2,643 shares worth $311,684. The insider RICHMOND TIMOTHY J. sold $2.15M. Schumacher Laura J sold $2.95 million worth of AbbVie Inc. (NYSE:ABBV) on Wednesday, February 28.

Investors sentiment decreased to 0.8 in Q4 2017. Its down 0.05, from 0.85 in 2017Q3. It dived, as 42 investors sold ABBV shares while 695 reduced holdings. 139 funds opened positions while 448 raised stakes. 1.06 billion shares or 0.35% more from 1.06 billion shares in 2017Q3 were reported. The Colorado-based Advsrs Asset has invested 0.73% in AbbVie Inc. (NYSE:ABBV). Washington Trust owns 56,824 shares. Shoker Inv Counsel reported 1.7% stake. Parkside Commercial Bank accumulated 12,263 shares. Papp L Roy & has invested 0.17% in AbbVie Inc. (NYSE:ABBV). Affinity Investment Ltd holds 0.1% of its portfolio in AbbVie Inc. (NYSE:ABBV) for 9,188 shares. Oarsman Capital has invested 1.85% in AbbVie Inc. (NYSE:ABBV). Adage Cap Prtn Group Limited Liability Corporation reported 2.17M shares. Woodstock Corp holds 1.68% of its portfolio in AbbVie Inc. (NYSE:ABBV) for 94,461 shares. Credit Agricole S A, a France-based fund reported 64,697 shares. Ifc Fl has 22,481 shares for 0.15% of their portfolio. Torray Ltd Liability has invested 0.15% of its portfolio in AbbVie Inc. (NYSE:ABBV). Cambridge Advsr owns 202,105 shares. 32,138 are held by Naples Global Advisors Limited Liability. Investors Asset Mgmt Of Georgia Ga Adv owns 10,317 shares.

Among 23 analysts covering Abbvie Inc (NYSE:ABBV), 10 have Buy rating, 2 Sell and 11 Hold. Therefore 43% are positive. Abbvie Inc had 91 analyst reports since July 21, 2015 according to SRatingsIntel. As per Thursday, January 4, the company rating was maintained by Jefferies. The firm earned “Buy” rating on Friday, September 15 by Jefferies. The stock of AbbVie Inc. (NYSE:ABBV) has “Buy” rating given on Friday, September 15 by Piper Jaffray. On Monday, October 31 the stock rating was downgraded by Credit Suisse to “Neutral”. Jefferies maintained the stock with “Buy” rating in Tuesday, January 16 report. The rating was maintained by UBS on Friday, October 13 with “Neutral”. The firm has “Hold” rating given on Sunday, July 30 by BMO Capital Markets. As per Monday, July 17, the company rating was maintained by Jefferies. As per Wednesday, April 6, the company rating was initiated by Societe Generale. The firm has “Buy” rating given on Sunday, October 29 by SunTrust.

Analysts await AbbVie Inc. (NYSE:ABBV) to report earnings on July, 27. They expect $1.97 EPS, up 38.73% or $0.55 from last year’s $1.42 per share. ABBV’s profit will be $3.13 billion for 13.53 P/E if the $1.97 EPS becomes a reality. After $1.87 actual EPS reported by AbbVie Inc. for the previous quarter, Wall Street now forecasts 5.35% EPS growth.

More notable recent AbbVie Inc. (NYSE:ABBV) news were published by: Fool.com which released: “5 Things AbbVie Investors Need to Know” on May 18, 2018, also Seekingalpha.com with their article: “Biotechs perk up ahead of ASCO abstract drop” published on May 16, 2018, Seekingalpha.com published: “AbbVie: Protection Kicks In” on April 25, 2018. More interesting news about AbbVie Inc. (NYSE:ABBV) were released by: Seekingalpha.com and their article: “Trump speech on drug prices light on specifics” published on May 11, 2018 as well as 247Wallst.com‘s news article titled: “Why One Old Stock Buyback Trick Is Working So Well for AbbVie” with publication date: May 01, 2018.

Bedell Frazier Investment Counseling Llc, which manages about $268.65M US Long portfolio, upped its stake in Gilead Sciences Inc (NASDAQ:GILD) by 29,536 shares to 99,125 shares, valued at $7.10M in 2017Q4, according to the filing.

More notable recent Horizon Pharma Public Limited Company (NASDAQ:HZNP) news were published by: Bizjournals.com which released: “Gilead, BioMarin among Bay Area drug makers shamed by FDA in generics ‘gaming’ list” on May 17, 2018, also Nasdaq.com with their article: “Horizon Pharma plc Announces the US Patent and Trademark Office Issuance of Additional Notices of Allowance With …” published on May 08, 2018, Nasdaq.com published: “Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)” on May 04, 2018. More interesting news about Horizon Pharma Public Limited Company (NASDAQ:HZNP) were released by: Streetinsider.com and their article: “Paulson’s 13F Shows New Stake in Goldcorp (GG), Increase in Discovery (DISCA), Viacom (VIAB) (more…)” published on May 15, 2018 as well as Nasdaq.com‘s news article titled: “Horizon Pharma plc Announces Sangita Iyer as a 2018 Healthcare Businesswomen’s Association Rising Star” with publication date: May 03, 2018.

Analysts await Horizon Pharma Public Limited Company (NASDAQ:HZNP) to report earnings on August, 6. They expect $0.33 EPS, down 19.51% or $0.08 from last year’s $0.41 per share. HZNP’s profit will be $54.47M for 11.34 P/E if the $0.33 EPS becomes a reality. After $0.03 actual EPS reported by Horizon Pharma Public Limited Company for the previous quarter, Wall Street now forecasts 1,000.00% EPS growth.

Bank Of America Corp, which manages about $597.43 billion US Long portfolio, upped its stake in Wisdomtree Tr (DLS) by 50,377 shares to 622,005 shares, valued at $47.77M in 2017Q4, according to the filing. It also increased its holding in Nushares Etf Tr by 25,114 shares in the quarter, for a total of 25,310 shares, and has risen its stake in Goldman Sachs Etf Tr.

Horizon Pharma Public Limited Company (NASDAQ:HZNP) Ratings Chart

Leave a Reply

Your email address will not be published. Required fields are marked *